Other therapeutic options for cancer management are emerging, such as the immunotherapy with mAbs (32–37), bi-specific T-cell engagers (BiTEs), a kind of mAbs, which are fusion proteins containing two antibody binding sites, one for tumor antigen on cancer cells, and other for simultaneous binding to CD3 on T-cells (38); Blinatumomab (39) and Anti-ROR1 BiTE (40) belong to this category. The gene discussed is ROR1; the disease is neoplasm.